GlobeImmune, Inc., today announced that on February 11, 2014, the company completed a $7.5 million private placement of convertible notes and warrants. Continue reading
February 13, 2014
Author Archives: kchristoffersen
October 27, 2013
GlobeImmune presents GI-4000 Phase 2 NSCLC data at IASLC Continue reading
October 15, 2013
GlobeImmune Announces Milestone Payment for Initiation of Phase 2 Clinical Trial for GS-4774 (Formerly GI-13020) Continue reading
September 04, 2013
April 18, 2013
GlobeImmune, Inc., today announced that Timothy C. Rodell, M.D. will present at the 12th Annual Needham Healthcare Conference on Tuesday, April 30, 2013 in New York. Continue reading
April 03, 2013
GlobeImmune, Inc., announced today the initiation of a Phase 2 clinical trial at the National Cancer Institute (NCI) to evaluate GI-6207 in subjects with medullary thyroid cancer (MTC). Continue reading
January 28, 2013
November 11, 2012
November 10, 2012
July 02, 2012